The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.
Human cytomegalovirus (HCMV) infection in utero can lead to congenital sensory neural hearing loss and mental retardation. Reactivation or primary infection can increase the morbidity and mortality in immune suppressed transplant recipients and AIDS patients. The current standard of care for HCMV disease is nucleoside analogs, which can be nephrotoxic. In addition resistance to current treatments is becoming increasingly common. In an effort to develop novel CMV treatments, we tested the effectiveness of the D-form of a novel heparan sulfate binding peptide, p5RD, at reducing infection of ganciclovir (GCV) resistant HCMVs in vitro and MCMV in vivo. HCMV infection was reduced by greater than 90% when cells were pretreated with p5RD. Because p5RDacts by a mechanism unrelated to those used by current antivirals, it was effective at reducing GCV resistant HCMVs by 85%. We show that p5RDis resistant to common proteases and serum inactivation, which likely contributed to its ability to significantly reduced infection of peritoneal exudate cells and viral loads in the spleen and the lungs in vivo. The ability of p5RDto reduce HCMV infectivity in vitro including GCV resistant HCMVs and MCMV infection in vivo suggests that this peptide could be a novel anti-CMV therapeutic.
University of Tennessee, Department of Microbiology, Knoxville, TN 37996, USA.
Elisabeth A
EA
Pitt
University of Tennessee, Department of Microbiology, Knoxville, TN 37996, USA.
Pranay
P
Dogra
University of Tennessee, Department of Microbiology, Knoxville, TN 37996, USA.
Ravi S
RS
Patel
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA.
Angela
A
Williams
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA; Department of Radiology, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA.
Jonathan S
JS
Wall
University of Tennessee, Department of Microbiology, Knoxville, TN 37996, USA. Electronic address: tsparer@utk.edu.
Tim E
TE
Sparer
D003587:Cytomegalovirus / Q000187:drug effects* / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000821:virology; D024882:Drug Resistance, Viral; D005347:Fibroblasts / Q000187:drug effects / Q000821:virology; D015774:Ganciclovir / Q000494:pharmacology; D006497:Heparan Sulfate / Q000378:metabolism*; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000821:virology; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D013154:Spleen / Q000187:drug effects / Q000821:virology; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D015774:Ganciclovir; D006497:Heparan Sulfate; D010455:Peptides
Cytomegalovirus; Ganciclovir; HCMV; Heparan sulfate; MCMV; Peptide; Protease resistance
PLoS Pathog. 2011 Jan 13;7(1):e1001256
21249233
Nat Prod Rep. 2002 Jun;19(3):312-31
12137280
J Gen Virol. 2006 Jul;87(Pt 7):1853-62
16760387
Expert Rev Vaccines. 2010 Nov;9(11):1303-14
21087108
J Infect Dis. 1998 Mar;177(3):770-3
9498461
Clin Microbiol Rev. 2010 Oct;23(4):689-712
20930070
BMC Bioinformatics. 2008 Jan 23;9:40
18215316
J Virol. 2016 Jun 24;90(14 ):6216-23
27122579
AAPS J. 2006 Jul 21;8(3):E466-78
17025264
Vaccine. 2013 Apr 18;31 Suppl 2:B197-203
23598482
Antiviral Res. 2006 Sep;71(2-3):154-63
16765457
Nat Rev Microbiol. 2004 Sep;2(9):704-20
15372081
J Vis Exp. 2010 Jan 28;(35):null
20110936
Molecules. 2011 Apr 26;16(5):3499-518
21522083
Drug Discov Today. 2015 Jan;20(1):122-8
25450771
J Clin Invest. 2001 Jul;108(2):169-73
11457867
Antimicrob Agents Chemother. 2011 Jan;55(1):382-4
21041510
J Virol. 2011 Nov;85(22):11638-45
21880752
J Clin Virol. 2004 Jun;30(2):115-33
15125867
J Biol Chem. 2011 Jul 15;286(28):25406-15
21596749
Clin Dev Immunol. 2013;2013:501801
24023565
Clin Microbiol Rev. 2009 Jan;22(1):99-126, Table of Contents
19136436
J Virol. 2015 May;89(9):5185-92
25717110
Antimicrob Agents Chemother. 2005 Jul;49(7):2710-5
15980340
Biochem Biophys Res Commun. 2013 Jun 21;436(1):85-9
23707811
PLoS Pathog. 2013;9(7):e1003493
23935483
PLoS One. 2015 May 18;10(5):e0126239
25992785
Curr Opin Pharmacol. 2008 Oct;8(5):616-9
18602024
J Infect Dis. 1995 Mar;171(3):576-83
7876604
Nat Protoc. 2010 Apr;5(4):725-38
20360767
PLoS Pathog. 2015 Feb 06;11(2):e1004640
25659098
Infect Chemother. 2013 Sep;45(3):260-71
24396627
Eur J Biochem. 1989 Jan 2;178(3):609-17
2521469
Arch Ophthalmol. 1996 Jul;114(7):809-14
8660163
Arch Virol. 1993;132(1-2):209-20
8102523
Herpes. 2005 Oct;12(2):50-5
16209862
J Virol. 2004 Sep;78(18):10023-33
15331735
Clin Infect Dis. 2002 Oct 1;35(7):866-72
12228824
J Infect Dis. 2002 Jan 15;185(2):162-9
11807689
Clin Infect Dis. 2007 Aug 15;45(4):439-47
17638191
Antimicrob Agents Chemother. 2010 Jun;54(6):2371-8
20385869
J Infect Dis. 2000 Oct;182(4):1234-8
10979924
J Infect Dis. 2002 Sep 15;186(6):760-8
12198609
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E586-94
21807994
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20037-42
18077432
Curr Protoc Immunol. 2008 Nov;Chapter 14:Unit 14.1
19016445
J Virol. 2006 Jan;80(2):710-22
16378974
J Med Virol. 2004 Sep;74(1):85-93
15258973
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14118-23
18768787
J Infect Dis. 1995 Jul;172(1):239-42
7797920
Med Res Rev. 2002 Jan;22(1):1-25
11746174
Virology. 1993 Apr;193(2):834-41
8384757
Antimicrob Agents Chemother. 2013 Oct;57(10):4751-60
23856778
Molecules. 2015 Apr 27;20(5):7657-82
25923515
J Clin Virol. 2006 Apr;35(4):474-7
16406798
Curr Opin Virol. 2012 Feb;2(1):37-42
22440964
Mt Sinai J Med. 1999 Mar;66(2):113-24
10100416
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8
16319222
J Clin Virol. 2011 Apr;50(4):287-91
21295516
J Virol. 2010 May;84(9):4469-80
20181688
J Gen Virol. 2008 Apr;89(Pt 4):853-65
18343825
Nature. 2007 Apr 26;446(7139):1030-7
17460664
Clin Microbiol Rev. 2009 Jan;22(1):76-98, Table of Contents
19136435